rss
Gut 50:425-427 doi:10.1136/gut.50.3.425
  • Occasional viewpoint

Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

  1. A K Burroughs1,
  2. R Groszmann2,
  3. J Bosch3,
  4. N Grace4,
  5. G Garcia-Tsao2,
  6. D Patch1,
  7. J C Garcia-Pagan3,
  8. L Dagher1
  1. 1Royal Free Hospital, Liver Transplantation and Hepatobiliary Medicine, London, UK
  2. 2Yale University School of Medicine, Department of Internal Medicine, Section of Digestive Disease, VA Medical Centre, West Haven, USA
  3. 3Hospital Clinic i Provincial de Barcelona, Hepatic Hemodynamic Laboratory, Barcelona, Spain
  4. 4Faulkner Hospital, Department of Gastroenterology, Boston, Massachusetts, USA
  1. Correspondence to:
    A K Burroughs, Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital NHS Trust, Pond Street, London NW3 2QG, UK;
    andrew.burroughs{at}talk21.com
  • Accepted 15 May 2001

Abstract

Chronic hepatitis C is a major healthcare problem. The response to antiviral therapy for patients with chronic hepatitis C has previously been defined biochemically and by PCR. However, changes in the hepatic venous pressure gradient (HVPG) may be considered as an adjunctive end point for the therapeutic evaluation of antiviral therapy in chronic hepatitis C. It is a validated technique which is safe, well tolerated, well established, and reproducible. Serial HVPG measurements may be the best way to evaluate response to therapy in chronic hepatitis C.

Footnotes